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Tissue-Specific Progenitor and Stem Cells
Bioactive Lipids and Circulating Progenitor Cells in
Patients With Cardiovascular Disease
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ABSTRACT
Bone marrow-derived progenitor cells are mobilized into the peripheral blood after acute myo-
cardial injury and in chronic ischemic heart disease. However, themechanisms responsible for this
mobilization are poorly understood.We examined the relationship between plasma levels of bio-
active lipids and number of circulating progenitor cells (CPCs) in patients (N = 437) undergoing
elective or emergent cardiac catheterization. Plasma levels of sphingosine-1 phosphate (S1P)
and ceramide-1 phosphate (C1P) were quantified using mass spectrometry. CPCs were assessed
using flow cytometry. S1P levels correlated with the numbers of CD341, CD341/CD1331, and
CD341/CXCR41 CPCs even after adjustment for potential confounding factors. However, no sig-
nificant correlation was observed between C1P levels and CPC count. Plasma levels of S1P corre-
lated with the number of CPCs in patients with coronary artery disease, suggesting an important
mechanistic role for S1P in stem cell mobilization. The therapeutic effects of adjunctive S1P ther-
apy to mobilize endogenous stem cells need to be investigated. STEM CELLS TRANSLATIONAL
MEDICINE 2016;5:1–5
SIGNIFICANCE
Bonemarrow-derived progenitor cells aremobilized after acutemyocardial injury and in chronic
ischemic heart disease. However, themechanisms responsible for thismobilization are poorly
understood. The relationship between plasma levels of the bioactive lipid sphingosine-1
phosphate (S1P) and circulating progenitor cells was examined in 437 patients undergoing
elective or emergent cardiac catheterization. S1P levels correlated with the numbers of
CD341 , CD341/CD1331 , and CD341/CXCR41 cells, even after adjustment for potential
confounding factors. These data suggest an important mechanistic role for S1P in stem cell
mobilization that can be explored therapeutically as an adjunctive in future cardiac regen-
erative studies.
INTRODUCTION
Circulating progenitor cells (CPCs) are mononu-
clear cells that originate primarily from the bone
marrow, differentiate into hematopoietic and
endothelial cells, and contribute to vascular
repair and cardiomyocyte regeneration [1–5].
We and others have shown that low CPC counts
are predictors of adverse cardiovascular events
and are likely biomarkers of regenerative poten-
tial [6, 7]. Studies using CPC mobilization as a
method to enhance cardiac recovery in heart
failure or after myocardial infarction have
achieved modest success, probably because of
incomplete understanding of the mechanisms
underlying mobilization and homing of regener-
ative cells.
Several chemokines, including vascular en-
dothelial growth factor (VEGF) and stromal cell
derived factor-1 (SDF-1), play an important role
in the recruitment of CPCs from the bone mar-
row [8, 9]. However, the exclusive role of these
chemokines has been debated [10]. After acute
myocardial infarction (AMI), matrix metallopro-
teinases (MMPs) and proteases are upregulated
in the myocardium [11], leading to the degrada-
tion of several chemokines [12]. More recently,
bioactive lipids, notably sphingosine-1 phos-
phate (S1P), that are resistant to MMPs have
been characterized as chemoattractants that
enhance mobilization and homing of stem
cells from the bone marrow [13, 14]. Raising
plasma S1P levels in a mouse model of AMI
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increased CPC mobilization and enhanced cardiac recovery
[15]. Whether an association between bioactive lipids and
CPC counts in patients with coronary artery disease (CAD)
exists is unclear and is the subject of this study. We
hypothesized that bioactive lipids would mobilize CPCs
and thus their levels will be associated with higher counts
of CPCs.
MATERIALS AND METHODS
Study Design
We examined the relationship between bioactive lipids and
CPCs in subjects (N = 437) recruited into the Emory Cardiovas-
cular Biobank, a prospective cohort consisting of patients
aged 20 to 90 years who were undergoing elective or emer-
gent cardiac catheterization. Subjects with congenital heart
disease, severe valvular heart disease, severe anemia, recent
blood transfusion, myocarditis, active inflammatory diseases,
and cancer were excluded. Obstructive CAD was defined
as .50% luminal narrowing in a major epicardial vessel.
The study was approved by the institutional review board
at Emory University. All subjects provided written informed
consent.
Quantitation of Bioactive Lipids
Arterial blood was collected in EDTA tubes and plasma was iso-
lated by centrifuging whole blood for 10 minutes at 800g. Lipids
were extracted from plasma using acidified organic solvents, as
previously described [16].
Measurement of Circulating Progenitor Cells Counts
Peripheral blood mononuclear cells were incubated with
fluorochrome-labeled monoclonal anti-human mouse anti-
bodies within 4 hours of blood draw. Cell populations en-
riched for CPCs were quantified using flow cytometry as
CD45dim cells coexpressing CD34, CD133, vascular endothe-
lial growth factor receptor 2 (VEGFR2), or CXCR4, and their
combination, as previously described [6]. The CD45dim pop-
ulation consists of CD341 cells with dim expression of
CD45, thus excluding hematopoietic CD341/CD45med and
CD341/CD45hi hematogones or bone marrow-derived early
B-cell precursors. Flow data were analyzed with FlowJo soft-
ware (Ashland, OR, http://www.flowjo.com). CPC popula-
tions are reported as absolute counts (cells per ml of whole
blood), determined using Accucheck Counting Beads (Thermo
Fisher Scientific Life Sciences, Waltham, MA, http://www.
thermofisher.com).
Statistical Analysis
Subject characteristics were reported as descriptive statis-
tics with means, medians, standard deviations, and ranges,
where appropriate. Correlation analyses were performed
using the Pearson’s correlation for normally distributed var-
iables and Spearman’s correlation for non-normally distrib-
uted variables. Cell counts were non-normally distributed
and were transformed (natural log[cell count11]) before
parametric analyses. Multivariable analyses using linear re-
gression of log-transformed outcomes variables adjusted for
age, sex, race (black vs. other), and body mass index, as well
variableswith a p value, .1 on univariable analysis. Analyses
were performed using IBM SPSS Statistics version 21 (IBM,
Armonk, NY, https://www.ibm.com).
RESULTS
Themajority of enrolledpatientswerewhitemen; themedianage
of the patients was 64 years. They had multiple CAD risk factors
and 57% had obstructive CAD (Table 1).
On univariable analyses, plasma S1P and C1P levels were
negatively correlated with male sex, history of myocardial in-
farction, hypertension, hyperlipidemia, and serum creatinine
level, whereas they positively correlated with high-density
and low-density lipoprotein levels. Previous myocardial infarc-
tion did not correlatewith total C1P levels andwas not included
in the model. After multivariable adjustments, only the creat-
inine level and hyperlipidemia remained independently associ-
ated with S1P levels (Table 2).
The number of CPCs (CD45dim cells), in particular CD341
(r = .187; p, .001), CD341/CD1331 (r = .217; p, .001), and
CD341/CXCR41 (r = .207; p, .001) cells correlated positively
with S1P levels. However, CD341/VEGFR21 cells did not sig-
nificantly correlate with S1P levels (r = 20.30; p = .531), and
Table 1. Demographics and clinical characteristics
Characteristic Dataa (N = 437)
Age, median, yr (SD) 64 (13)
Male sex, n (%) 282 (65)
Black race, median (SD) 102 (23)
Body mass index, median, kg/m2 (SD) 29 (6)
Clinical characteristics
Systolic blood pressure, mmHg 137 (21)
Diastolic blood pressure, mmHg 70 (22)
Hypertension, n (%) 197 (45)
Hyperlipidemia, n (%) 174 (40)
Diabetes mellitus, n (%) 160 (37)
Obstructive coronary artery disease, n (%) 247 (57)
Previous myocardial infarction, n (%) 114 (26)
Heart failure, n (%) 125 (29)
Ejection fraction, n (%) 53 (13)
LDL, median (SD), mg/dl 93 (42)
HDL, median (SD), mg/dl 42 (15)
Creatinine, median (IQR), mg/dl 1.0 (0.89–1.3)
Bioactive lipids, median (IQR)
Sphingosine-1 phosphate, mM 0.84 (0.64–1.0)
Ceramide-1 phosphate, mM 40 (18–85)
Circulating progenitor cells, median (IQR)
CD341, cells/ml 1.82 (1.16–2.75)
CD341/CD1331, cells/ml 0.77 (0.45–1.20)
CD341/CXCR41, cells/ml 1.01 (0.65–1.54)
CD341/VEGFR21, cells/ml 0.18 (0.10–0.34)
aCategorical data are provided as n (%). Continuous variables are given
as mean (SD) or median (interquartile range) where noted.
Abbreviations: HDL, high-density lipoprotein; IQR, interquartile range;
LDL, low-density lipoprotein.
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CPC counts did not correlate with C1P levels. Onmultivariable
analysis, S1P levels were significantly associated with the
aforementioned CPC populations (Fig. 1; Table 2).
DISCUSSION
The role of bone marrow-derived progenitor cells in cardiac
repair is still being studied in randomized trials; however,
strong evidence suggests that CPCs are mobilized after car-
diac injury [17, 18]. In the largest cohort to date examining
the relationship between plasma bioactive lipids and circulat-
ing stem cells, we demonstrated a strong correlation between
plasma S1P levels and the number of CPCs in patients with
CAD.
We and others showed that the degree of CPC mobiliza-
tion correlates with functional cardiac recovery [19] and
clinical outcomes [6, 20]. Ischemic myocardial injury acti-
vates the immune system, including the complement cas-
cade [21], which plays an important role in the release of
bioactive lipids such as S1P from blood [22] and endothelial
cells [23], thus increasing S1P’s transendothelial gradient
[14]. Of note, number of CD341/VEGFR21 cells did not cor-
relate with plasma S1P levels. This could be intrinsic to this
cell population, which could be more responsive to VEGF. In-
terestingly, in an animal model of AMI, temporary elevation
of S1P in the plasma resulted in enhanced bonemarrow stem
cell mobilization and cardiac recovery [15]. In this report, we
demonstrated a strong association between plasma S1P lev-
els andmobilized CPCs in a large cohort of patients with CAD,
a finding that is in agreement with our report in patients with
acute coronary syndrome [14]. Although the present data
do not prove a causal relationship between plasma S1P lev-
els and CPC mobilization, combined with findings from our
previous mechanistic studies, the results support an important role
for S1P in modulating peripheral stem cell trafficking [13].
Clinical Implications
In conclusion, the bioactive lipid S1P strongly correlated with
CPC levels in patients with CAD in this study. Future studies
using adjunctive therapy with S1P to enhance bone marrow
mobilization of stem cells are needed to investigate its ther-
apeutic benefit.
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